NASDAQ: IMAImagenebio Inc Stock
$7.09-0.42 (-5.59%)
Updated Feb 2, 2026
IMA Price
$7.09
Fair Value Price
-$0.32
Market Cap
$79.28M
52 Week Low
$5.71
52 Week High
$19.20
P/E
-0.89x
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$45.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$47M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMA Overview
Ikena Oncology Incorporated is developing medicines tailored to patient groups with specific unmet needs. Its lead oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional factor in the Hippo signaling pathway. The company is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, IK-175, an oral inhibitor of aryl hydrocarbon receptor, and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. Ikena Oncology was incorporated in 2016 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMA
Ranked#454 of 484
Ranked#454 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $167.29 | A | |
| $6.63 | A | |
| $345.00 | A |
Be the first to know about important IMA news, forecast changes, insider trades & much more!
IMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMA ($7.09) is overvalued by 2,316.54% relative to our estimate of its Fair Value price of -$0.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMA ($7.09) is not significantly undervalued (2,316.54%) relative to our estimate of its Fair Value price of -$0.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMA due diligence checks available for Premium users.
Valuation
IMA fair value
Fair Value of IMA stock based on Discounted Cash Flow (DCF)
Price
$7.09
Fair Value
-$0.32
Undervalued by
2,316.54%
IMA ($7.09) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMA ($7.09) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.89x
Industry
167.44x
Market
42.86x
IMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
5.49x
IMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.8M
Profit Margin
0%
IMA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$160.9M
Liabilities
$21.0M
Debt to equity
0.15
IMA's short-term assets ($147.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMA's short-term assets ($147.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.6M
Investing
-$37.3M
Financing
$0.0
IMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMA vs Biotech Stocks
Imagenebio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.